Management of severe toxic epidermal necrolysis in children.
Toxic epidermal necrolysis (TEN) is a severe form of erythema multiforme that results in extensive epidermal sloughing; the condition is associated with a mortality of up to 70%. From 1991 to 1998, 10 children with severe toxic epidermal necrolysis were referred to a regional pediatric burn facility. Wounds were managed with strategy involving prevention of wound desiccation and superinfection, including the frequent use of biologic wound coverings. Children unable to guard their airway because of extensive oropharyngeal involvement were prophylactically intubated. Enteral nutrition was stressed. Steroids were not used and antibiotics were administered to managed specific foci of infection only. The 2 boys and 8 girls had an average age of 7.2+/-1.8 years (range 6 months to 15 years) and sloughed surface area of 76+/-6% of the body surface (range 50 to 95%). Antibiotics (3 children), anticonvulsants (3 children), nonsteroidals (2 children), and viral syndrome or unknown agents (2 children) were felt to have triggered the syndrome. Six children (60%) required intubation for an average of 9.7+/-1.8 days (range 2 to 14 days). Buccal mucosal involvement occurred in 9 (90%) and ocular involvement in 9 (90%). Although infectious complications were common (2 pneumonias, 2 urinary infections, 1 bacteremia, 2 central line infections, and 2 candidemias), all children survived after lengths of stay in the burn unit averaging 19+/-3 (range 6 to 40) days. The most common long-term morbidity was keratitis sicca (2 children, 20%), finger nail deformities (3 children, 30%), and variegated skin pigment changes (5 children, 50%). Although having both a cutaneous and visceral wound that predispose them to infectious complications, most children with TEN will survive if managed with a strategy emphasizing biologic wound closure, intensive nutritional support, and early detection and treatment of septic foci. Burn units have the resource set required to manage severe TEN and early referral of such children may have a favorable impact on survival.
Sheridan
R L
RL
Shriners Burns Hospital and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. sheridan.robert@mgh.harvard.edu
Weber
J M
JM
Schulz
J T
JT
Ryan
C M
CM
Low
H M
HM
Tompkins
R G
RG
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications; D001684:Biological Dressings; D002056:Burns / Q000150:complications; D002648:Child; D002675:Child, Preschool; D004750:Enteral Nutrition; D005260:Female; D006801:Humans; D007223:Infant; D007440:Intubation; D007634:Keratitis / Q000150:complications; D008297:Male; D009264:Nails, Malformed / Q000150:complications; D010859:Pigmentation Disorders / Q000150:complications; D011014:Pneumonia / Q000150:complications; D013262:Stevens-Johnson Syndrome / Q000628:therapy*; D014552:Urinary Tract Infections / Q000150:complications
D000900:Anti-Bacterial Agents